One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Atacicept—it’s not over until the wolf-lady sings (or maybe howls)
David A Isenberg, Celia J F Lin
doi : 10.1093/rheumatology/keac523
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1359–1361
Structural changes in the sacroiliac joint imaging in axial spondyloarthritis: from conventional radiography to magnetic resonance imaging?
Laura Pina Vegas, Pascal Claudepierre
doi : 10.1093/rheumatology/keac521
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1362–1363
Dr Yellapragada SubbaRow: the forgotten figure in the history of methotrexate
Narendra K Bagri, Atreya Ramanan, Athimalaipet V Ramanan
doi : 10.1093/rheumatology/keac520
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1364–1365
PET/CT in giant cell arteritis: will the best imaging technique please stand up?
Lien Moreel, Albrecht Betrains, Daniel Blockmans
doi : 10.1093/rheumatology/keac550
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1366–1367
JAK inhibitors in autoinflammatory syndromes? The long road from drug development to daily clinical use
Philippe Guilpain
doi : 10.1093/rheumatology/keac592
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1368–1369
Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Mark D Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Senvar, Sofia Tosounidou, Maud van de Venne, Louise Warburton, David Williams, Chee-Seng Yee, Caroline Gordon, Ian Giles, BSR Standards, Audit and Guidelines Working Group
doi : 10.1093/rheumatology/keac558
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1370–1387
Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice
Karen Schreiber, Margreta Frishman, Mark D Russell, Mrinalini Dey, Julia Flint, Alexander Allen, Amy Crossley, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Naz Senvar, Sofia Tosounidou, Maud van de Venne, Louise Warburton, David Williams, Chee-Seng Yee, Caroline Gordon, Ian Giles, BSR Standards, Audit and Guidelines Working Group
doi : 10.1093/rheumatology/keac559
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1388–1397
Treating spondyloarthritis early: does it matter? Results from a systematic literature review
Dafne Capelusnik, Diego Benavent, Désirée van der Heijde, Robert Landewé, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compán, Sofia Ramiro
doi : 10.1093/rheumatology/keac532
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1398–1409
To summarize evidence on the relationship between early treatment (definition based on symptom/disease duration or radiographic damage) and treatment clinical response in patients with SpA.
Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis
Xiangpeng Wang, Ziyi Tang, Tianwen Huang, Huifang Hu, Yaxi Zhao, Yi Liu
doi : 10.1093/rheumatology/keac515
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1410–1416
To evaluate the effect of MTX withdrawal on disease activity and remission rate in patients at target after treatment with biologic DMARDs (bDMARDs)/targeted synthetic DMARDs (tsDMARDs) plus MTX.
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Raji Rajalingam, Steve Peterson, Fareen Hassan, Soumya D Chakravarty, Christine Contré, Alison Armstrong, Wolf-Henning Boehncke, Christopher Ritchlin
doi : 10.1093/rheumatology/keac500
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1417–1425
The IL-23 p19-subunit inhibitor guselkumab has been previously compared with other targeted therapies for PsA through network meta-analysis (NMA). The objective of this NMA update was to include new guselkumab COSMOS trial data, and two key comparators: the IL-23 inhibitor risankizumab and the Janus kinase (JAK) inhibitor upadacitinib.
Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis
Andrés González GarcÃa, Julián Fernández-MartÃn, Ã�ngel Robles Marhuenda
doi : 10.1093/rheumatology/keac481
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1426–1435
Idiopathic multicentric Castleman disease (iMCD) is an infrequent and life-threatening disorder characterized by systemic inflammatory symptoms, generalized lymphadenopathy, polyclonal lymphocyte proliferation and organ dysfunction caused by a hyperinflammatory state.
Type H vessels—a bridge connecting subchondral bone remodelling and articular cartilage degeneration in osteoarthritis development
Yuan Liu, Hui-Qi Xie, Bin Shen
doi : 10.1093/rheumatology/keac539
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1436–1444
Recent studies have shed light on the cellular and molecular mechanisms that link subchondral bone remodelling and angiogenesis in knee osteoarthritis (OA).
Is vaccination against COVID-19 associated with autoimmune rheumatic disease flare? A self-controlled case series analysis
Georgina Nakafero, Matthew J Grainge, Tim Card, Christian D Mallen, Jonathan S Nguyen Van-Tam, Hywel C Williams, Abhishek Abhishek
doi : 10.1093/rheumatology/keac484
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1445–1450
To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and autoimmune rheumatic disease (AIRD) flare.
Immune checkpoint inhibitor–induced arthralgia is tightly associated with improved overall survival in cancer patients
Ayaka Maeda, Kaoru Takase-Minegishi, Yohei Kirino, Naoki Hamada, Yosuke Kunishita, Ryusuke Yoshimi, Akira Meguro, Ho Namkoong, Nobuyuki Horita, Hideaki Nakajima, Yokohama City University irAE Working Group
doi : 10.1093/rheumatology/keac519
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1451–1459,
COVID-19 vaccine hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort
Christopher McMaster, David F L Liew, Susan Lester, Adam Rischin, Rachel J Black, Vibhasha Chand, Ashley Fletcher, Marissa N Lassere, Lyn March, Philip C Robinson, Rachelle Buchbinder, Catherine L Hill
doi : 10.1093/rheumatology/keac503
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1460–1466
To determine COVID-19 vaccine hesitancy rates in inflammatory arthritis patients and identify factors associated with changing vaccine hesitancy over time.
Anti-PM-Scl antibodies–positive patients encompass three different groups with distinct prognoses
Paul Breillat, Kuberaka Mariampillai, Paul Legendre, Pauline Martins, Bertrand Dunogue, Jean Luc Charuel, Makoto Miyara, Claire Goulvestre, Romain Paule, Helene Vanquaethem, Felix Ackermann, Olivier Benveniste, Hilario Nunes, Luc Mouthon, Yves Allenbach, Yurdagul Uzunhan
doi : 10.1093/rheumatology/keac508
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1467–1475
To help identify homogeneous subgroups among patients with anti-PM-scleroderma-antibodies (PM-Scl-Abs) positive auto-immune diseases regardless of diagnostic classifications.
Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting
Benjamin Birkner, Jürgen Rech, Edmund Edelmann, Frank Verheyen, Georg Schett, Tom Stargardt
doi : 10.1093/rheumatology/keac472
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1476–1484
We aim to provide real-world evidence on the effectiveness of patient-individual tapering of DMARDs for patients with RA in daily clinical practice using medical records and claims data.
Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study
Simone Parisi, Anna Zanetti, Greta Carrara, Carlo Alberto Scirè, Annamaria Iagnocco, Georgios Filippou, the STARTER Investigators
doi : 10.1093/rheumatology/keac518
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1485–1492
This study is a sub-analysis from the patient cohort of the STARTER (Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission) study.
In patients with acute mono/oligoarthritis, a targeted ultrasound scanning protocol shows great accuracy for the diagnosis of gout and CPPD
Edoardo Cipolletta, Emilio Filippucci, Abhishek Abhishek, Jacopo Di Battista, Gianluca Smerilli, Marco Di Carlo, Ferdinando Silveri, Rossella De Angelis, Fausto Salaffi, Walter Grassi, Andrea Di Matteo
doi : 10.1093/rheumatology/keac479
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1493–1500
To determine an US scanning protocol with the best accuracy for the diagnosis of gout and CPPD in patients with acute mono/oligo-arthritis of unknown origin.
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Jiandong Zhou, Xuejin Liu, Oscar Hou-In Chou, Lifang Li, Sharen Lee, Wing Tak Wong, Qingpeng Zhang, Carlin Chang, Tong Liu, Gary Tse, Fengshi Jing, Bernard Man Yung Cheung
doi : 10.1093/rheumatology/keac509
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1501–1510
The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks.
Prevalence of undiagnosed axial spondyloarthritis in inflammatory bowel disease patients with chronic back pain: secondary care cross-sectional study
Chong Seng Edwin Lim, Mark Tremelling, Louise Hamilton, Matthew Kim, Alexander Macgregor, Tom Turmezei, Karl Gaffney
doi : 10.1093/rheumatology/keac473
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1511–1518
To elucidate the prevalence of undiagnosed rheumatology-verified diagnosis of axial spondyloarthritis (RVD-axSpA) in patients attending routine secondary care IBD clinics with chronic back pain.
The influence of age on the prevalence of inflammatory and structural MRI lesions in the sacroiliac joints of patients with and without axial spondyloarthritis
Xenofon Baraliakos, Anna Kuehn, Styliani Tsiami, Uta Kiltz, Martin Fruth, Juergen Braun
doi : 10.1093/rheumatology/keac505
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1519–1525
To compare the influence of age on inflammatory (bone marrow oedema [BME]) and structural (fat lesions [FL], erosions and ankylosis) MRI lesions in the sacroiliac joints (SIJ) of patients with and without axial spondyloarthritis (axSpA).
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials
Ian N Bruce, Ronald F van Vollenhoven, Eric F Morand, Richard A Furie, Susan Manzi, William B White, Gabriel Abreu, Raj Tummala
doi : 10.1093/rheumatology/keac491
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1526–1534
Glucocorticoid sparing is a key priority for SLE management. We evaluated the effects of sustained glucocorticoid tapering in patients with SLE.
Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis
Stylianos Panopoulos, Sophie Mavrogeni, Charalambos Vlachopoulos, Petros P Sfikakis
doi : 10.1093/rheumatology/keac504
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1535–1542
Cardiac magnetic resonance imaging (CMRI) is increasingly used to evaluate cardiac involvement in SSc. We assessed changes, including inflammatory and/or fibrotic myocardial lesions detected by CMRI, following therapeutic interventions for SSc-associated symptomatic myocarditis.
A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials
Robyn T Domsic, Thomas A Medsger, Jr, Shiyao Gao, Maureen Laffoon, Suiyuan Huang, Stephen Wisniewski, Cathie Spino, Virginia Steen, Robert Lafyatis, Dinesh Khanna
doi : 10.1093/rheumatology/keac501
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1543–1551
Clinical trials in early diffuse SSc have consistently shown a placebo group response with a declining modified Rodnan skin score (mRSS), with negative outcomes. Our objective was to identify strategies using clinical characteristics or laboratory values to improve trial design.
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients
Fabio Cacciapaglia, Paolo Airò, Marco Fornaro, Paolo Trerotoli, Enrico De Lorenzis, Addolorata Corrado, Maria Grazia Lazzaroni, Gerlando Natalello, Fabio Montini, Alberto Altomare, Livio Urso, Lucrezia Verardi, Silvia Laura Bosello, Francesco Paolo Cantatore, Florenzo Iannone
doi : 10.1093/rheumatology/keac512
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1552–1558
Survival and death prognostic factors of SSc patients varied during the past decades. We aimed to update the 5- and 10-year survival rates and identify prognostic factors in a multicentre cohort of Italian SSc patients diagnosed after 2009.
Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database
Michele Iudici, Denis Mongin, Elise Siegert, Patricia E Carreira, Jörg Distler, Jörg Henes, Elisabetta Zanatta, Eric Hachulla, Giacomo De Luca, Carolina de Souza Müller, Tânia Santiago, José-Luis Tandaipan, Breno Valdetaro Bianchi, Maria De Santis, Anna-Maria Hoffmann-Vold, Armando Gabrielli, Oliver Distler, Delphine Sophie Courvoisier, EUSTAR collaborators
doi : 10.1093/rheumatology/keac533
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1559–1567
To estimate the prevalence of long-term exposure to glucocorticoids (GCs) and to identify factors associated with, and variations in prescribing practices over time and across recruiting countries.
PET/CT of cranial arteries for a sensitive diagnosis of giant cell arteritis
Thomas Thibault, Bastien Durand-Bailloud, Agnès Soudry-Faure, Hélène Greigert, Clément Drouet, Hervé Devilliers, André Ramon, Yannick Bejot, Laurent Martin, Catherine Creuzot-Garcher, Nicolas Falvo, Sylvain Audia, Alexandre Cochet, Bernard Bonnotte, Jean-Louis Alberini, Maxime Samson
doi : 10.1093/rheumatology/keac430
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1568–1575
To investigate the performance of cranial PET/CT for the diagnosis of GCA.
Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study
Giuseppe Barilaro, Alexandra Esteves, Carlo Della Rocca, Albert Perez-Isidro, Olga Araujo, Gilberto Pires da Rosa, Estibaliz Ruiz-Ortiz, Dolors Tà ssies Penella, Odette Viñas, Joan Carles Reverter, Ricard Cervera, Gerard Espinosa
doi : 10.1093/rheumatology/keac485
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1576–1585
To assess the effect of the average adjusted global APS score (aGAPSS) over time on recurrence of clinical manifestations in APS patients through a retrospective longitudinal study.
Predicting lymphoma in Sjögren’s syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording
Salvatore De Vita, Miriam Isola, Chiara Baldini, Andreas V Goules, Loukas G Chatzis, Luca Quartuccio, Alen Zabotti, Ivan Giovannini, Valentina Donati, Francesco Ferro, Maria Teresa Rizzo, Valeria Manfrè, Enrico Pegolo, Michael Voulgarelis, Francesco Zaja, Renato Fanin, Christos Masaoutis, Dimitra Rontogianni, Dimitrios I Fotiadis, Maurilio Ponzoni, Athanasios G Tzioufas
doi : 10.1093/rheumatology/keac470
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1586–1593
Parotid swelling (PSW) is a major predictor of non-Hodgkin’s lymphoma (NHL) in primary SS (pSS). However, since detailed information on the time of onset and duration of PSW is scarce, this was investigated to verify whether it may lead to further improved prediction. NHL localization was concomitantly studied to evaluate the role of the parotid gland microenvironment in pSS-related lymphomagenesis.
JAK inhibitors in difficult-to-treat adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis
Louise Gillard, Jacques Pouchot, Fleur Cohen-Aubart, Isabelle Koné-Paut, Gaël Mouterde, Martin Michaud, Héloïse Reumaux, Léa Savey, Alexandre Belot, Bruno Fautrel, Stéphane Mitrovic on behalf of the CRI (Club Rhumatismes et Inflammation)
doi : 10.1093/rheumatology/keac440
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1594–1604,
Excessive and inappropriate production of pro-inflammatory cytokines plays a key role in Still’s disease. Janus kinase inhibitor (JAKi) agents mainly block pro-inflammatory cytokine pathways, notably IL-6 and IFN. The objective was to assess the efficacy and safety of JAKi agents in difficult-to-treat systemic JIA or adult-onset Still’s disease (AOSD).
Standardized nailfold capillaroscopy in children with rheumatic diseases: a worldwide study
Karin Melsens, Maurizio Cutolo, Dieneke Schonenberg-Meinema, Ivan Foeldvari, Maria C Leone, Yora Mostmans, Valérie Badot, Rolando Cimaz, Joke Dehoorne, Ellen Deschepper, Tracy Frech, Johanna Hernandez-Zapata, Francesca Ingegnoli, Archana Khan, Dorota Krasowska, Hartwig Lehmann, Ashima Makol, Miguel A Mesa-Navas, Malgorzata Michalska-Jakubus, Ulf Müller-Ladner, Laura Nuño-Nuño, Rebecca Overbury, Carmen Pizzorni, Mislav Radic, Divya Ramadoss, Angelo Ravelli, Silvia Rosina, Clara Udaondo, Merlijn J van den Berg, Ariane L Herrick, Alberto Sulli, Vanessa Smith, for the EULAR Study Group on Microcirculation in Rheumatic Diseases
doi : 10.1093/rheumatology/keac487
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1605–1615
To standardly assess and describe nailfold videocapillaroscopy (NVC) assessment in children and adolescents with juvenile rheumatic and musculoskeletal diseases (jRMD) vs healthy controls (HCs).
Comparing Canadian paediatric rheumatology practice to the 2019 ACR Juvenile Idiopathic Arthritis guidelines: results from the CAPRI Registry
Jonathan Park, Michelle Batthish, Roberta A Berard, Gaëlle Chédeville, Jean-Philippe Proulx-Gauthier, Dax G Rumsey, Lori B Tucker, Stephanie Wong, Jaime Guzman, for the CAPRI Registry Investigators
doi : 10.1093/rheumatology/keac468
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1616–1620
To identify differences between baseline Canadian JIA practices and the 2019 ACR guidelines for JIA.
Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status
Sinead Maguire, Samar Al-Emadi, Paula Alba, Mathia Cecilia Aguiar, Talal Al Lawati, Gelsomina Alle, Bonnie Bermas, Suleman Bhana, Anic Branimir, Inita Bulina, Megan Clowse, Karina Cogo, Iris Colunga, Claire Cook, Karen J Cortez, Kathryn Dao, Milena Gianfrancesco, Monique Gore-Massey, Laure Gossec, Rebecca Grainger, Jonathon Hausman, Tiffany Y T Hsu, Kimme Hyrich, Carolina Isnardi, Yumeko Kawano, Rachael Kilding, Daria A Kusevich, Saskia Lawson-Tovey, Jean Liew, Eoghan McCarthy, Anna Montgumery, Sebastian Moyano, Noreen Nasir, Ivan Padjen, Charalampos Papagoras, Naomi J Patel, Mariana Pera, Cecilia Pisoni, Guillermo Pons-Estel, Antonio L Quiambao, Rosana Quintana, Eric Ruderman, Sebastian Sattui, Veronica Savio, Savino Sciascia, Marieta Sencarova, Rosa Serrano Morales, Faizah Siddique, Emily Sirotich, Jeffrey Sparks, Anja Strangfeld, Paul Sufka, Helen Tanner, Yohana Tissera, Zachary Wallace, Marina L Werner, Leanna Wise, Angus B Worthing, JoAnn Zell, Julija Zepa, Pedro M Machado, Jinoos Yazdany, Philip Robinson, Richard Conway on behalf of the COVID-19 Global Rheumatology Alliance
doi : 10.1093/rheumatology/keac534
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1621–1626
To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.
Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis
Céleste J T van der Togt, David F Ten Cate, Bart J F van den Bemt, Janette Rahamat-Langendoen, Nathan den Broeder, Alfons A den Broeder
doi : 10.1093/rheumatology/keac486
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1627–1630
In patients with RA treated with (ultra-)low-dose rituximab (RTX), we investigated the association of dosing and timing of RTX on seroconversion after a third coronavirus disease 2019 (COVID-19) vaccination and the persistence of humoral response after a two-dose vaccination.
Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort
Mikhail Protopopov, Fabian Proft, Stephanie Wichuk, Pedro M Machado, Robert G Lambert, Ulrich Weber, Susanne Juhl Pedersen, Mikkel Østergaard, Joachim Sieper, Martin Rudwaleit, Xenofon Baraliakos, Walter P Maksymowych, Denis Poddubnyy
doi : 10.1093/rheumatology/keac432
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1631–1635
To compare MRI and conventional radiography of SI joints for detection of structural lesions typical for axial spondyloarthritis (axSpA).
AOSD endotypes based on immune cell profiles: patient stratification with hierarchical clustering analysis
Ruru Guo, Xuesong Liu, Yixuan Li, Xinyu Meng, Rui Li, Xiaoxiang Chen, Liangjing Lu
doi : 10.1093/rheumatology/keac439
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1636–1644,
This study aimed to analyse the immune cell profiles of adult-onset Still’s disease (AOSD) and to stratify disease-associated endotypes.
Association between popliteal artery wall thickness and structural progression in patients with symptomatic knee osteoarthritis
Yuanyuan Wang, Ega Wirayoda Pontoh, Sultana Monira Hussain, Yuan Z Lim, Graeme Jones, Catherine L Hill, Anita E Wluka, Andrew Tonkin, Changhai Ding, Flavia M Cicuttini
doi : 10.1093/rheumatology/keac469
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1645–1651
There is increasing evidence for the involvement of vascular disease in the pathogenesis of knee OA. Popliteal artery wall thickness can be used as a surrogate marker of atherosclerosis. We examined the association between popliteal artery wall thickness and knee cartilage volume in individuals with symptomatic knee OA.
Metformin attenuates osteoarthritis by targeting chondrocytes, synovial macrophages and adipocytes
Delong Li, Guangfeng Ruan, Yan Zhang, Yang Zhao, Zhaohua Zhu, Qianhua Ou, Hong Huang, Jieli Chen, Weiyu Han, Su’an Tang, Jia Li, Liang Wang, Tianyu Chen, Xiaochun Bai, Daozhang Cai, Changhai Ding
doi : 10.1093/rheumatology/keac467
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1652–1661
To investigate the therapeutic effect and mechanism of metformin on knee OA in normal diet (ND) mice or high-fat diet (HFD)-induced obese mice.
Longitudinal global transcriptomic profiling of preclinical systemic sclerosis reveals molecular changes associated with disease progression
Chiara Bellocchi, Lorenzo Beretta, Xuan Wang, Marka A Lyons, Maurizio Marchini, Maurizio Lorini, Vincenzo Carbonelli, Nicola Montano, Shervin Assassi
doi : 10.1093/rheumatology/keac492
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1662–1668
To investigate peripheral blood cell (PBCs) global gene expression profile of SSc at its preclinical stage (PreSSc) and to characterize the molecular changes associated with progression to a definite disease over time.
Allelic expression imbalance in articular cartilage and subchondral bone refined genome-wide association signals in osteoarthritis
Rodrigo Coutinho de Almeida, Margo Tuerlings, Yolande Ramos, Wouter Den Hollander, Eka Suchiman, Nico Lakenberg, Rob G H H Nelissen, Hailiang Mei, Ingrid Meulenbelt
doi : 10.1093/rheumatology/keac498
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1669–1676
To present an unbiased approach to identify positional transcript single nucleotide polymorphisms (SNPs) of osteoarthritis (OA) risk loci by allelic expression imbalance (AEI) analyses using RNA sequencing of articular cartilage and subchondral bone from OA patients.
A panel of plasma microRNAs improves the assessment of surrogate markers of cardiovascular disease in rheumatoid arthritis patients
Didac Llop, Daiana Ibarretxe, Núria Plana, Roser Rosales, Delia Taverner, LluÃs Masana, Joan Carles Vallvé, Silvia Paredes
doi : 10.1093/rheumatology/keac483
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1677–1686
Patients with RA present increased risk of cardiovascular (CV) disease compared with the general population. Moreover, CV risk factors that have a causal relationship with atherosclerosis do not seem to fully explain the accelerated process that they exhibit.
Dendritic cells drive profibrotic inflammation and aberrant T cell polarization in systemic sclerosis
José Alberto Choreño-Parra, Diana Cervantes-Rosete, Luis Armando Jiménez-Ã�lvarez, Gustavo RamÃrez-MartÃnez, José Eduardo Márquez-GarcÃa, Alfredo Cruz-Lagunas, Ana Yelli Magaña-Sánchez, Guadalupe Lima, Humberto López-Maldonado, Emanuel Gaytán-Guzmán, Adrian Caballero, Rosario Fernández-Plata, Janette Furuzawa-Carballeda, Criselda Mendoza-Milla, Maria del Carmen Navarro-González, Luis Llorente, JoaquÃn Zúñiga, Tatiana SofÃa RodrÃguez-Reyna
doi : 10.1093/rheumatology/keac489
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1687–1698
SSc is a devastating autoimmune disease characterized by fibrosis and obliterative vasculopathy affecting the skin and visceral organs. While the processes mediating excessive extracellular matrix deposition and fibroblast proliferation are clear, the exact link between autoimmunity and fibrosis remains elusive.
Novel mutation and expanding phenotype in IRF2BP2 deficiency
Julia Körholz, Anastasia Gabrielyan, Henrike Lisa Sczakiel, Livia Schulze, Manuela Rejzek, Martin W Laass, Nicolai Leuchten, Oliver Tiebel, Diana Aust, Karsten Conrad, Nadja Röber, Eva-Maria Jacobsen, Nadja Ehmke, Reinhard Berner, Nadja Lucas, Minae A Lee-Kirsch, Ralf Wiedemuth, Joachim Roesler, Axel Roers, Timm Amendt, Catharina Schuetz
doi : 10.1093/rheumatology/keac575
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1699–1705
Inborn errors of immunity manifest with susceptibility to infection but may also present with immune dysregulation only. According to the European Society for Immunodeficiencies Registry about 50% of inborn errors of immunity are classified as common variable immunodeficiencies (CVID).
Similar effect of co-administration of methotrexate and folic acid for the treatment of arthritis compared to separate administration
Elisa Dalix, Mathieu Maalouf, Sylvie Peyroche, Arnaud Vanden-Bossche, Charles-Antoine Arthaud, Sophie Hodin, Rüdiger B Müller, Hubert Marotte
doi : 10.1093/rheumatology/keac579
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1706–1710
MTX is the recommended first-line treatment for RA associated with folic acid (FA) to reduce side effects related to MTX. Here, we proposed to test a co-administration of MTX with FA in the rat adjuvant-induced arthritis (AIA) on efficacy.
Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study
Nadège Cordel, Benoît Dechelotte, Fabienne Jouen, Janine A Lamb, Hector Chinoy, Paul New, Jiri Vencovsky, Herman Mann, Angeles S Galindo-Feria, Lara Dani, Albert Selva-O’Callaghan, Victoria P Werth, Adarsh Ravishankar, Océane Landon-Cardinal, Benoit Tressières, Olivier Boyer
doi : 10.1093/rheumatology/keac577
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1711–1715
To assess the role of the anti-TIF1γ auto-antibody (aAb) IgG2 isotype as a biomarker of cancer in anti-TIF1γ aAb-positive adult DM.
Obituary: Professor Justin Charles Mason
Taryn Youngstein, Dorian Haskard
doi : 10.1093/rheumatology/keac699
Rheumatology, Volume 62, Issue 4, April 2023, Pages 1716–1717
Correction to: Ruxolitinib inhibits IFNγ-stimulated Sjögren’s salivary gland MSC HLA-DR expression and chemokine-dependent T cell migration
doi : 10.1093/rheumatology/keac588
Rheumatology, Volume 62, Issue 4, April 2023, Page 1718
Correction to: Which inflamed tissues explain a positive metatarsophalangeal squeeze test? A large imaging study to clarify a common diagnostic procedure
doi : 10.1093/rheumatology/keac516
Rheumatology, Volume 62, Issue 4, April 2023, Page 1719
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Mark D Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Senvar, Sofia Tosounidou, Maud van de Venne, Louise Warburton, David Williams, Chee-Seng Yee, Caroline Gordon, Ian Giles, BSR Standards, Audit and Guidelines Working Group
doi : 10.1093/rheumatology/keac551
Rheumatology, Volume 62, Issue 4, April 2023, Pages e48–e88
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice
Karen Schreiber, Margreta Frishman, Mark D Russell, Mrinalini Dey, Julia Flint, Alexander Allen, Amy Crossley, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Naz Senvar, Sofia Tosounidou, Maud van de Venne, Louise Warburton, David Williams, Chee-Seng Yee, Caroline Gordon, Ian Giles, BSR Standards, Audit and Guidelines Working Group
doi : 10.1093/rheumatology/keac552
Rheumatology, Volume 62, Issue 4, April 2023, Pages e89–e104
Correlation between soluble TREM2 and anti-GluN2 antibody in lupus patients with diffuse psychiatric and neuropsychological syndromes
Yoshiyuki Arinuma, Yasuhiro Hasegawa, Tomoki Tanaka, Yu Matsueda, Tatsuhiko Wada, Kenji Oku, Kunihiro Yamaoka
doi : 10.1093/rheumatology/keac488
Rheumatology, Volume 62, Issue 4, April 2023, Pages e105–e106
Is there a gender gap in global rheumatology leadership?
Tayyeba Khursheed, Ghita Harifi, Pavel V Ovseiko, Harish G Shekar, Humeira Badsha, Latika Gupta
doi : 10.1093/rheumatology/keac499
Rheumatology, Volume 62, Issue 4, April 2023, Pages e107–e108
Procalcitonin can increase during activation of adult-onset Still’s disease (AOSD) in the absence of an ınfection focus
Reşit Yıldırım, Sedanur Oğuzman, Döndü Üsküdar Cansu, Mustafa Dinler, Cengiz Korkmaz
doi : 10.1093/rheumatology/keac511
Rheumatology, Volume 62, Issue 4, April 2023, Pages e109–e110
Elevated serum levels of soluble T cell immunoglobulin and mucin-containing-molecule-3 in patients with idiopathic inflammatory myopathy
Yueyuan Zhou, Sheng Ye, Leiyi Yang, Geng Yin, Qibing Xie
doi : 10.1093/rheumatology/keac510
Rheumatology, Volume 62, Issue 4, April 2023, Pages e111–e113
Absence of overexpression of KIR3DL2 on CD4+ T cells and NK cells in patients with axial spondyloarthritis
Guillaume Larid, Sophie Trijau, Clothilde Barral, Pierre Lafforgue, Thao Pham
doi : 10.1093/rheumatology/keac546
Rheumatology, Volume 62, Issue 4, April 2023, Pages e114
Sulfasalazine induced leukocytoclastic vasculitis resulting in gangrene
Laith Alamlih, Layth AL-Karaja, Dana Amro, Mutaz Alnatsheh
doi : 10.1093/rheumatology/keac490
Rheumatology, Volume 62, Issue 4, April 2023, Pages e117–e118
DWI scalp dot sign: superficial temporal artery restricted diffusion in giant cell arteritis
Eleanor Taylor, Francesca Tona, Victoria Singh-Curry, Marius Venter, Maresa Carulli, Colin Tench, Taryn Youngstein, Luke Dixon
doi : 10.1093/rheumatology/keac502
Rheumatology, Volume 62, Issue 4, April 2023, Pages e119–e121
Atypical polyarticular juvenile idiopathic arthritis revealing multicentric reticulohistiocytosis with pulmonary involvement
Anna Gaussem, Perrine Dusser, Van Huynh, Caroline Galeotti, Adrien Schvartz, Léa Jaume, Linda Rossi-Semerano, Isabelle Koné-Paut, Charlotte Borocco
doi : 10.1093/rheumatology/keac480
Rheumatology, Volume 62, Issue 4, April 2023, Pages e122–e123
The bias in the nomenclature of large-vessel vasculitis
Chetan B Mukhtyar
doi : 10.1093/rheumatology/keac527
Rheumatology, Volume 62, Issue 4, April 2023, Pages e124–e126
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?
Jacopo Ciaffi, Elena Vanni, Giancarlo Facchini, Marco Miceli, Francesco Ursini
doi : 10.1093/rheumatology/keac537
Rheumatology, Volume 62, Issue 4, April 2023, Pages e127–e128
Comment on: Efficacy and safety of tocilizumab in Behçet’s syndrome with refractory arterial lesions: a single-centre observational cohort study in China
Rıza Can Kardaş, Hamit Küçük
doi : 10.1093/rheumatology/keac493
Rheumatology, Volume 62, Issue 4, April 2023, Pages e129–e130
Comment on: Efficacy and safety of tocilizumab in Behçet’s syndrome with refractory arterial lesions: a single-centre observational cohort study in China: reply
Hua Zhong, Tian Liu
doi : 10.1093/rheumatology/keac494
Rheumatology, Volume 62, Issue 4, April 2023, Page e131
Comment on: Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen
Rubén Queiro-Silva
doi : 10.1093/rheumatology/keac554
Rheumatology, Volume 62, Issue 4, April 2023, Pages e132–e133,
Comment on: Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen: reply
Telma Thrastardottir, Elana Meer, Arna Hauksdottir, Bjorn Gudbjornsson, Sigurdur Yngvi Kristinsson, Alexis Ogdie, Thorvardur Jon Love
doi : 10.1093/rheumatology/keac555
Rheumatology, Volume 62, Issue 4, April 2023, Pages e134–e135
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy
Bradly A Kimbrough, Elie Naddaf, Kenneth J Warrington, Rafael E Jimenez, Matthew J Koster
doi : 10.1093/rheumatology/keac506
Rheumatology, Volume 62, Issue 4, April 2023, Pages e136–e137
Flare-up of mucocutaneous leishmaniasis following infliximab discontinuation and antiparasitic therapy in a patient with juvenile idiopathic arthritis
Florent Amatore, Floriane Lebas, Aurélie Haffner, Emmanuel Delaporte
doi : 10.1093/rheumatology/keac513
Rheumatology, Volume 62, Issue 4, April 2023, Pages e138–e139
